Skip to content
2000
Volume 32, Issue 15
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Introduction

Chemotherapy therapies are effective in treating cancer, but they can have harmful effects on the cardiovascular system. This study explores the possible role of metformin in reducing the cardiac damage caused by chemotherapy.

Methods

In this scoping review, we conducted a comprehensive literature search on electronic databases (PubMed, Scopus, and Web of Science (ISI)) until November 2023. The manuscript was screened regarding the role of metformin in chemotherapy-induced cardiotoxicity. Finally, 26 papers were selected after double screening.

Results

Chemotherapy has the potential to damage and cause cell death in the heart, resulting in molecular, biochemical, and histological changes compared to an untreated group. However, co-treatment with metformin may offer protection by preventing or reversing these harmful effects on cardiac cells. Metformin's cardioprotective properties are thought to be due to its ability to modulate oxidative stress, inflammation, autophagy, and the apoptotic pathway.

Conclusion

The present study strongly suggests that metformin is an effective solution to chemotherapy-induced cardiotoxicity. Metformin can alleviate the harmful effects of chemotherapy on the heart by affecting oxidative stress, inflammation, autophagy, and apoptosis pathways. However, it is essential to note that the use of metformin may have some drawbacks, as it is a non-targeted therapy and could potentially reduce the effectiveness of targeted cancer drugs. Despite this, the potential benefits of using metformin in clinical settings cannot be ignored. Further studies are necessary to determine the specifics of this interaction. Still, the promising results of this review suggest that metformin may be an essential tool in the fight against chemotherapy-induced cardiotoxicity.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673320425240806051215
2024-08-16
2025-10-30

  • From This Site

    /content/journals/cmc/10.2174/0109298673320425240806051215
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ApostolovaN. IannantuoniF. GruevskaA. MuntaneJ. RochaM. VictorV.M. Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions.Redox Biol.20203410151710.1016/j.redox.2020.10151732535544
     [Google Scholar]
  2. HuangJ. ChangZ. LuQ. ChenX. NajafiM. Nobiletin as an inducer of programmed cell death in cancer: A review.Apoptosis: Int. J. Prog. cell. death2022275-6297310
     [Google Scholar]
  3. BoutryJ. TissotS. UjvariB. CappJ.P. GiraudeauM. NedelcuA.M. ThomasF. The evolution and ecology of benign tumors.Biochim. Biophys. Acta Rev. Cancer20221877118864310.1016/j.bbcan.2021.18864334715267
     [Google Scholar]
  4. PomerantzM.M. FreedmanM.L. The genetics of cancer risk.Cancer J.201117641642210.1097/PPO.0b013e31823e538722157285
     [Google Scholar]
  5. NagaiH. KimY.H. Cancer prevention from the perspective of global cancer burden patterns.J. Thorac. Dis.20179344845110.21037/jtd.2017.02.7528449441
     [Google Scholar]
  6. DebelaD.T. MuzazuS.G.Y. HeraroK.D. NdalamaM.T. MeseleB.W. HaileD.C. KituiS.K. ManyazewalT. New approaches and procedures for cancer treatment: Current perspectives.SAGE Open Med.20219p. 2050312121103436610.1177/2050312121103436634408877
     [Google Scholar]
  7. BaskarR. LeeK.A. YeoR. YeohK.W. Cancer and radiation therapy: Current advances and future directions.Int. J. Med. Sci.20129319319910.7150/ijms.363522408567
     [Google Scholar]
  8. NajafiM. MortezaeeK. RahimifardM. FarhoodB. Haghi-AminjanH. The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study.Life Sci.202025711805110.1016/j.lfs.2020.11805132634426
     [Google Scholar]
  9. MortezaeeK. AhmadiA. Haghi-AminjanH. KhanlarkhaniN. SalehiE. Shabani NashtaeiM. FarhoodB. NajafiM. SahebkarA. Thyroid function following breast cancer chemotherapy: A systematic review.J. Cell. Biochem.20191208121011210710.1002/jcb.2877131021464
     [Google Scholar]
  10. BoussiosS. PentheroudakisG. KatsanosK. PavlidisN. Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management.Ann. Gastroenterol.201225210611824713845
     [Google Scholar]
  11. SăftescuS. PopoviciD. OpreanC. NegruA. HaiducA. StancaS. MalițaD.C. VolovățS. NegruȘ. Determining factors of renal dysfunction during cisplatin chemotherapy.Exp. Ther. Med.20202118310.3892/etm.2020.951633363594
     [Google Scholar]
  12. ShakirD. RasulK.I. Chemotherapy induced cardiomyopathy: Pathogenesis, monitoring and management.J. Clin. Med. Res.20091181210.4021/jocmr2009.02.122522505958
     [Google Scholar]
  13. ValaeiK. TaherkhaniS. AraziH. SuzukiK. Cardiac oxidative stress and the therapeutic approaches to the intake of antioxidant supplements and physical activity.Nutrients20211310348310.3390/nu1310348334684484
     [Google Scholar]
  14. YahyapourR. AminiP. SaffarH. RezapoorS. MotevaseliE. ChekiM. FarhoodB. NouruziF. ShabeebD. Eleojo MusaA. NajafiM. Metformin protects against radiation-induced heart injury and attenuates the upregulation of dual oxidase genes following rat’s chest irradiation.Int. J. Mol. Cell. Med.20187319320231565651
     [Google Scholar]
  15. NajafiM. ChekiM. HassanzadehG. AminiP. ShabeebD. MusaA.E. Protection from radiation-induced damage in rat’s ileum and colon by combined regimens of melatonin and metformin: A histopathological study.Antiinflamm. Antiallergy Agents Med. Chem.202019218018910.2174/187152301866619071816192831438832
     [Google Scholar]
  16. Ismail HassanF. DidariT. BaeeriM. GholamiM. Haghi-AminjanH. KhalidM. Navaei-NigjehM. RahimifardM. SolgiS. AbdollahiM. MojtahedzadehM. Metformin attenuates brain injury by inhibiting inflammation and regulating tight junction proteins in septic rats.Cell J.202022Suppl. 1293732779431
     [Google Scholar]
  17. KasznickiJ. SliwinskaA. DrzewoskiJ. Metformin in cancer prevention and therapy.Ann. Transl. Med.2014265725333032
     [Google Scholar]
  18. WuX. XuW.W. HuanX. WuG. LiG. ZhouY.H. NajafiM. Mechanisms of cancer cell killing by metformin: A review on different cell death pathways.Mol. Cell. Biochem.2023478119721410.1007/s11010‑022‑04502‑435771397
     [Google Scholar]
  19. FarhadiR. DanialiM. BaeeriM. ForoumadiR. GholamiM. HassaniS. MirzababaeiS. Haghi-AminjanH. Navaei-NigjehM. RahimifardM. AbdollahiM. Metformin ameliorates cardiopulmonary toxicity induced by chlorpyrifos.Drug Chem. Toxicol.202447564966110.1080/01480545.2023.223952337501618
     [Google Scholar]
  20. DidariT. HassaniS. BaeeriM. Navaei-NigjehM. RahimifardM. Haghi-AminjanH. GholamiM. NejadS.M. HassanF.I. MojtahedzadehM. AbdollahiM. Short-term effects of metformin on cardiac and peripheral blood cells following cecal ligation and puncture-induced sepsis.Drug Res.202171525726410.1055/a‑1322‑747833348389
     [Google Scholar]
  21. TriccoA.C. LillieE. ZarinW. O’BrienK.K. ColquhounH. LevacD. MoherD. PetersM.D.J. HorsleyT. WeeksL. HempelS. AklE.A. ChangC. McGowanJ. StewartL. HartlingL. AldcroftA. WilsonM.G. GarrittyC. LewinS. GodfreyC.M. MacdonaldM.T. LangloisE.V. Soares-WeiserK. MoriartyJ. CliffordT. TunçalpÖ. StrausS.E. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation.Ann. Intern. Med.2018169746747310.7326/M18‑085030178033
     [Google Scholar]
  22. BramerW.M. MilicJ. MastF. Reviewing retrieved references for inclusion in systematic reviews using EndNote.J. Med. Libr. Assoc.20171051848710.5195/jmla.2017.11128096751
     [Google Scholar]
  23. ShokrzadehM. AhmadiA. ChabraA. NaghshvarF. SalehiF. HabibiE. Haghi-AminjanH. An ethanol extract of Origanum vulgare attenuates cyclophosphamide-induced pulmonary injury and oxidative lung damage in mice.Pharm. Biol.201452101229123610.3109/13880209.2013.87990824646304
     [Google Scholar]
  24. Haghi-AminjanH. FarhoodB. RahimifardM. DidariT. BaeeriM. HassaniS. HosseiniR. AbdollahiM. The protective role of melatonin in chemotherapy-induced nephrotoxicity: A systematic review of non-clinical studies.Expert Opin. Drug Metab. Toxicol.201814993795010.1080/17425255.2018.151349230118646
     [Google Scholar]
  25. El kikiS.M. OmranM.M. MansourH.H. HasanH.F. Metformin and/or low dose radiation reduces cardiotoxicity and apoptosis induced by cyclophosphamide through SIRT-1/SOD and BAX/Bcl-2 pathways in rats.Mol. Biol. Rep.20204775115512610.1007/s11033‑020‑05582‑532537703
     [Google Scholar]
  26. AlhowailA.H. AldubayanM.A. The impact of metformin on the development of hypothyroidism and cardiotoxicity induced by cyclophosphamide, methotrexate, and fluorouracil in rats.Pharmaceuticals2023169131210.3390/ph1609131237765120
     [Google Scholar]
  27. SamadiM. Haghi-AminjanH. SattariM. Hooshangi ShayestehM.R. BameriB. ArmandehM. NaddafiM. EghbalM.A. AbdollahiM. The role of taurine on chemotherapy-induced cardiotoxicity: A systematic review of non-clinical study.Life Sci.202126511881310.1016/j.lfs.2020.11881333275984
     [Google Scholar]
  28. Asensio-LopezM.C. Sanchez-MasJ. Pascual-FigalD.A. de TorreC. ValdesM. LaxA. Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced by doxorubicin in cardiomyocytes.Free Radic. Biol. Med.201467192910.1016/j.freeradbiomed.2013.11.00324231192
     [Google Scholar]
  29. KobashigawaL.C. XuY.C. PadburyJ.F. TsengY.T. YanoN. Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: An in vitro study.PLoS One201498e10488810.1371/journal.pone.010488825127116
     [Google Scholar]
  30. ZhangS. WeiX. ZhangH. WuY. JingJ. HuangR. ZhouT. HuJ. WuY. LiY. YouZ. Doxorubicin downregulates autophagy to promote apoptosis-induced dilated cardiomyopathy via regulating the AMPK/mTOR pathway.Biomed. Pharmacother.202316211469110.1016/j.biopha.2023.11469137060659
     [Google Scholar]
  31. SatyamS.M. BairyL.K. ShettyP. SainathP. BharatiS. AhmedA.Z. SinghV.K. AshwalA.J. Metformin and dapagliflozin attenuate doxorubicin-induced acute cardiotoxicity in wistar rats: An electrocardiographic, biochemical, and histopathological approach.Cardiovasc. Toxicol.202323210711910.1007/s12012‑023‑09784‑836790727
     [Google Scholar]
  32. VanJ. HahnY. SilversteinB. LiC. CaiF. WeiJ. KatikiL. MehtaP. LivatovaK. DelPozzoJ. Metformin inhibits autophagy, mitophagy and antagonizes doxorubicin-induced cardiomyocyte death.Int. J. Drug Discov. Pharm.2023213751
     [Google Scholar]
  33. AlzokakyA.A. Al-KarmalawyA.A. SalehM.A. AbdoW. FarageA.E. BelalA. AbourehabM.A.S. AntarS.A. Metformin ameliorates doxorubicin-induced cardiotoxicity targeting HMGB1/TLR4/NLRP3 signaling pathway in mice.Life Sci.202331612139010.1016/j.lfs.2023.12139036649752
     [Google Scholar]
  34. LiaoH.H. DingW. ZhangN. ZhouZ.Y. LingZ. LiW.J. ChenS. TangQ.Z. Activation of AMPKα2 attenuated doxorubicin-induced cardiotoxicity via inhibiting lipid peroxidation associated ferroptosis.Free Radic. Biol. Med.202320527529010.1016/j.freeradbiomed.2023.06.00437331642
     [Google Scholar]
  35. AleisaA.M. Al-RejaieS.S. BakheetS.A. Al-BekairiA.M. Al-ShabanaO.A. Al-MajedA. Al-YahyaA.A. QureshiS. Protective effect of Metformin on cardiac and hepatic toxicity induced by adriamycin in swiss albino mice.Asian Journal of Biochemistry2008329910810.3923/ajb.2008.99.108
     [Google Scholar]
  36. AleisaA.M. Al-RejaieS.S. BakheetS.A. Al-BekariA.M. Al-ShabanahO.A. Al-MajedA. Al-YahyaA.A. QureshiS. Effect of metformin on clastogenic and biochemical changes induced by adriamycin in swiss albino mice.Mutat. Res. Genet. Toxicol. Environ. Mutagen.20076341-29310010.1016/j.mrgentox.2007.06.00517693128
     [Google Scholar]
  37. KelleniM.T. AminE.F. AbdelrahmanA.M. Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats: Impact of oxidative stress, inflammation, and apoptosis.J. toxicology2015142481310.1155/2015/424813
     [Google Scholar]
  38. ShetaA. ElsakkarM. HamzaM. SolaimanA. Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in adult male albino rats.Hum. Exp. Toxicol.201635111227123910.1177/096032711562768526818447
     [Google Scholar]
  39. ShatyM.H. Al-EzziM.I. ArifI.S. BasilD. Effect of metformin on inflammatory markers involved in cardiotoxicity induced by doxorubicin.J. Res. Pharm. Techno201912125815582110.5958/0974‑360X.2019.01007.2
     [Google Scholar]
  40. ShatyM.H. ArifI.S. Al-EzziM.I. HannaD.B. Metformin attenuate fibrosis in both acute and chronic doxorubicin cardiotoxicity in rabbits.J. Pharm. Sci. Research201810615591565
     [Google Scholar]
  41. ZilinyiR. CzompaA. CzeglediA. GajtkoA. PitukD. LekliI. TosakiA. The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: The role of autophagy.Molecules2018235118410.3390/molecules2305118429762537
     [Google Scholar]
  42. ChenJ. ZhangS. PanG. LinL. LiuD. LiuZ. MeiS. ZhangL. HuZ. ChenJ. LuoH. WangY. XinY. YouZ. Modulatory effect of metformin on cardiotoxicity induced by doxorubicin via the MAPK and AMPK pathways.Life Sci.202024911749810.1016/j.lfs.2020.11749832142765
     [Google Scholar]
  43. ArinnoA. ManeechoteC. KhuanjingT. OngnokB. PrathumsapN. ChunchaiT. ArunsakB. KerdphooS. ShinlapawittayatornK. ChattipakornS.C. ChattipakornN. Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics.Biochem. Pharmacol.202119211474310.1016/j.bcp.2021.11474334453902
     [Google Scholar]
  44. AgabaA. EbadaM. EmaraH. Protective effect of metformin on doxorubicin-induced cardiomyopathy in the adult male albino rats (Light and Electron Microscopic Study).Int. J. Med. Al.Azhar20210010.21608/aimj.2021.72417.1458
     [Google Scholar]
  45. MackayA.D. MarchantE.D. MunkD.J. WattR.K. HansenJ.M. ThomsonD.M. HancockC.R. Multitissue analysis of exercise and metformin on doxorubicin-induced iron dysregulation.Am. J. Physiol. Endocrinol. Metab.20193165E922E93010.1152/ajpendo.00140.201830888858
     [Google Scholar]
  46. Asensio-LópezM.C. LaxA. Pascual-FigalD.A. ValdésM. Sánchez-MásJ. Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system.Free Radic. Biol. Med.201151101861187110.1016/j.freeradbiomed.2011.08.01521907790
     [Google Scholar]
  47. Asensio-LópezM.C. Sánchez-MásJ. Pascual-FigalD.A. AbenzaS. Pérez-MartínezM.T. ValdésM. LaxA. Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity.Free Radic. Biol. Med.20135718820010.1016/j.freeradbiomed.2012.09.00923000260
     [Google Scholar]
  48. ArgunM. ÜzümK. SönmezM.F. ÖzyurtA. DeryaK. ÇilenkK.T. UnalmışS. PamukcuÖ. BaykanA. NarinF. ElmalıF. NarinN. Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.Anatol. J. Cardiol.201616423424126642465
     [Google Scholar]
  49. MontazeriV. GhahremaniM.H. MontazeriH. HasanzadM. SafaviD.M. AyatiM. ChehraziM. Arefi MoghaddamB. OstadS.N. A preliminary study of ner and mmr pathways involved in chemotherapy response in bladder transitional cell carcinoma: Impact on progression-free survival.Iran. J. Pharm. Res.202019135536532922493
     [Google Scholar]
  50. Rastegar-PouyaniN. MontazeriV. MarandiN. AliebrahimiS. AndalibM. JafarzadehE. MontazeriH. OstadS.N. The impact of cancer-associated fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in bladder cancer: A comparison between recurrent and non-recurrent patient-derived CAFs.Cancer Invest.202341765667110.1080/07357907.2023.223757637462514
     [Google Scholar]
  51. Moini JazaniA. ArabzadehA. Haghi-AminjanH. Nasimi Doost AzgomiR. The role of ginseng derivatives against chemotherapy-induced cardiotoxicity: A systematic review of non-clinical studies.Front. Cardiovasc. Med.202310102236010.3389/fcvm.2023.102236036844721
     [Google Scholar]
  52. NageebM.M. SaadawyS.F. AttiaS.H. Breast milk mesenchymal stem cells abate cisplatin-induced cardiotoxicity in adult male albino rats via modulating the AMPK pathway.Sci. Rep.20221211755410.1038/s41598‑022‑22095‑236266413
     [Google Scholar]
  53. Le TourneauC. RaymondE. FaivreS. Sunitinib: A novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).Ther. Clin. Risk Manag.20073234134810.2147/tcrm.2007.3.2.34118360643
     [Google Scholar]
  54. KuburasR. GharaneiM. HaussmannI. MaddockH. SandhuH. Metformin protects against sunitinib-induced cardiotoxicity: Investigating the role of AMPK.J. Cardiovasc. Pharmacol.202279679980710.1097/FJC.000000000000125635266920
     [Google Scholar]
  55. Shyam SunderS. SharmaU.C. PokharelS. Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management.Signal Transduct. Target. Ther.20238126210.1038/s41392‑023‑01469‑637414756
     [Google Scholar]
  56. ShayestehM.R.H. Haghi-AminjanH. MousaviM.J. MomtazS. AbdollahiM. The protective mechanism of cannabidiol in cardiac injury: A systematic review of non- clinical studies.Curr. Pharm. Des.201925222499250710.2174/221032790966619071010310331291873
     [Google Scholar]
  57. DauganM. Dufaÿ WojcickiA. d'HayerB. BoudyV. Metformin: An anti-diabetic drug to fight cancer.Pharm. Res.2016113Pt A675685
     [Google Scholar]
  58. TossettaG. Metformin improves ovarian cancer sensitivity to paclitaxel and platinum-based drugs: A review of in vitro findings.Int. J. Mol. Sci.202223211289310.3390/ijms23211289336361682
     [Google Scholar]
  59. HuaY. ZhengY. YaoY. JiaR. GeS. ZhuangA. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing.J. Transl. Med.202321140310.1186/s12967‑023‑04263‑837344841
     [Google Scholar]
  60. MomtazS. BaeeriM. RahimifardM. Haghi-AminjanH. HassaniS. AbdollahiM. Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cellsJ. Cell. Biochem.201912046209622210.1002/jcb.2790930474871
     [Google Scholar]
  61. BaeeriM. RahimifardM. DaghighiS.M. KhanF. SalamiS.A. Moini-NodehS. Haghi-AminjanH. BayramiZ. RezaeeF. AbdollahiM. Cannabinoids as anti-ROS in aged pancreatic islet cells.Life Sci.202025611796910.1016/j.lfs.2020.11796932553926
     [Google Scholar]
  62. HabibiP. OstadS.N. HeydariA. AliebrahimiS. MontazeriV. ForoushaniA.R. MonazzamM.R. Ghazi-KhansariM. GolbabaeiF. Effect of heat stress on DNA damage: A systematic literature review.Int. J. Biometeorol.202266112147215810.1007/s00484‑022‑02351‑w36178536
     [Google Scholar]
  63. BaeeriM. DidariT. KhalidM. Mohammadi-NejadS. DaghighiS.M. FarhadiR. RahimifardM. BayramiZ. Haghi-AminjanH. ForoumadiR. GholamiM. AbdollahiM. Molecular evidence of the inhibitory potential of melatonin against NaAsO2-induced aging in male rats.Molecules20212621660310.3390/molecules2621660334771016
     [Google Scholar]
  64. WuB.B. LeungK.T. PoonE.N.Y. Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity.Int. J. Mol. Sci.2022233191210.3390/ijms2303191235163838
     [Google Scholar]
  65. AlbanoG.D. GagliardoR.P. MontalbanoA.M. ProfitaM. Overview of the mechanisms of oxidative stress: Impact in inflammation of the airway diseases.Antioxidants202211112237
     [Google Scholar]
  66. ZorovD.B. JuhaszovaM. SollottS.J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release.Physiol. Rev.201494390995010.1152/physrev.00026.201324987008
     [Google Scholar]
  67. GoriniS. De AngelisA. BerrinoL. MalaraN. RosanoG. FerraroE. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib.Oxid. Med. Cell. Longev.2018201811510.1155/2018/758273029743983
     [Google Scholar]
  68. Diniz VilelaD. Gomes PeixotoL. TeixeiraR.R. Belele BaptistaN. Carvalho CaixetaD. Vieira de SouzaA. MachadoH.L. PereiraM.N. Sabino-SilvaR. EspindolaF.S. The role of metformin in controlling oxidative stress in muscle of diabetic rats.Oxid. Med. Cell. Longev.201620161910.1155/2016/697862527579154
     [Google Scholar]
  69. WangY. BranickyR. NoëA. HekimiS. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling.J. Cell Biol.201821761915192810.1083/jcb.20170800729669742
     [Google Scholar]
  70. CollinF. Chemical basis of reactive oxygen species reactivity and involvement in neurodegenerative diseases.Int. J. Mol. Sci.20192010240710.3390/ijms2010240731096608
     [Google Scholar]
  71. HasanvandA. The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: A new perspective for treatment and prevention of diseases.Inflammopharmacology202230377578810.1007/s10787‑022‑00980‑635419709
     [Google Scholar]
  72. AyalaA. MuñozM.F. ArgüellesS. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal.Oxid. Med. Cell. Longev.2014201413110.1155/2014/36043824999379
     [Google Scholar]
  73. RastaldoR. PagliaroP. CappelloS. PennaC. MancardiD. WesterhofN. LosanoG. Nitric oxide and cardiac function.Life Sci.2007811077979310.1016/j.lfs.2007.07.01917707439
     [Google Scholar]
  74. Asensio-LópezM.C. SolerF. Pascual-FigalD. Fernández-BeldaF. LaxA. Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes.PLoS One2017122e017280310.1371/journal.pone.017280328245258
     [Google Scholar]
  75. MancardiD. MezzanotteM. ArrigoE. BarinottiA. RoettoA. Iron overload, oxidative stress, and ferroptosis in the failing heart and liver.AntioxidantsBasel, Switzerland202110121864
     [Google Scholar]
  76. KatsarouA. PantopoulosK. Hepcidin therapeutics.Pharmaceuticals201811412710.3390/ph1104012730469435
     [Google Scholar]
  77. WuZ. BaiY. QiY. ChangC. JiaoY. BaiY. GuoZ. Metformin ameliorates ferroptosis in cardiac ischemia and reperfusion by reducing NOX4 expression via promoting AMPKα.Pharm. Biol.202361188689610.1080/13880209.2023.221270037288723
     [Google Scholar]
  78. AbazariM.F. NasiriN. KariziS.Z. NejatiF. Haghi-AminjanH. NorouziS. PiriP. EstakhrL. FaradonbehD.R. KohandaniM. DaliriK. SanadgolN. AskariH. An updated review of various medicinal applications of p-co umaric acid: From antioxidative and anti-inflammatory properties to effects on cell cycle and proliferation.Mini Rev. Med. Chem.202121152187220110.2174/18755607MTEzjMzQo233459233
     [Google Scholar]
  79. HosseiniA. SamadiM. BaeeriM. RahimifardM. Haghi-AminjanH. The neuroprotective effects of melatonin against diabetic neuropathy: A systematic review of non-clinical studies.Front. Pharmacol.20221398449910.3389/fphar.2022.98449936120309
     [Google Scholar]
  80. FurmanD. CampisiJ. VerdinE. Carrera-BastosP. TargS. FranceschiC. FerrucciL. GilroyD.W. FasanoA. MillerG.W. MillerA.H. MantovaniA. WeyandC.M. BarzilaiN. GoronzyJ.J. RandoT.A. EffrosR.B. LuciaA. KleinstreuerN. SlavichG.M. Chronic inflammation in the etiology of disease across the life span.Nat. Med.201925121822183210.1038/s41591‑019‑0675‑031806905
     [Google Scholar]
  81. FlorescuM. CintezaM. VinereanuD. Chemotherapy-induced cardiotoxicity.Maedica201381596724023601
     [Google Scholar]
  82. BhagatA. ShresthaP. KleinermanE.S. The innate immune system in cardiovascular diseases and its role in doxorubicin-induced cardiotoxicity.Int. J. Mol. Sci.202223231464910.3390/ijms23231464936498974
     [Google Scholar]
  83. CsapoM. LazarL. Chemotherapy-induced cardiotoxicity: Pathophysiology and prevention.Clujul medical2014873135142
     [Google Scholar]
  84. LawrenceT. The nuclear factor NF-kappaB pathway in inflammation.Cold Spring Harb. Perspect. Biol.200916a00165110.1101/cshperspect.a00165120457564
     [Google Scholar]
  85. SarkhailP. NavidpourL. RahimifardM. HosseiniN.M. SouriE. Bioassay-guided fractionation and identification of wound healing active compound from Pistacia vera L. hull extract.J. Ethnopharmacol.202024811233510.1016/j.jep.2019.11233531654800
     [Google Scholar]
  86. DuttaS. ShahR.B. SinghalS. DuttaS.B. BansalS. SinhaS. HaqueM. Metformin: A review of potential mechanism and therapeutic utility beyond diabetes.Drug Des. Devel. Ther.2023171907193210.2147/DDDT.S40937337397787
     [Google Scholar]
  87. SaishoY. Metformin and inflammation: Its potential beyond glucose-lowering effect.Endocr. Metab. Immune Disord. Drug Targets201515319620510.2174/187153031566615031612401925772174
     [Google Scholar]
  88. KimY.C. GuanK.L. mTOR: A pharmacologic target for autophagy regulation.J. Clin. Invest.20151251253210.1172/JCI7393925654547
     [Google Scholar]
  89. DanH.C. CooperM.J. CogswellP.C. DuncanJ.A. TingJ.P.Y. BaldwinA.S. Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK.Genes Dev.200822111490150010.1101/gad.166230818519641
     [Google Scholar]
  90. YangZ. KlionskyD.J. An overview of the molecular mechanism of autophagy.Curr. Top. Microbiol. Immunol.200933513210.1007/978‑3‑642‑00302‑8_119802558
     [Google Scholar]
  91. HaleA.N. LedbetterD.J. GawrilukT.R. RuckerE.B.III Autophagy.Autophagy20139795197210.4161/auto.2427324121596
     [Google Scholar]
  92. SuiX. ChenR. WangZ. HuangZ. KongN. ZhangM. HanW. LouF. YangJ. ZhangQ. WangX. HeC. PanH. Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment.Cell Death Dis.2013410e83810.1038/cddis.2013.35024113172
     [Google Scholar]
  93. QianM. FangX. WangX. Autophagy and inflammation.Clin. Transl. Med.201761e2410.1186/s40169‑017‑0154‑528748360
     [Google Scholar]
  94. PangY. WuL. TangC. WangH. WeiY. Autophagy-inflammation interplay during infection: balancing pathogen clearance and host inflammation.Front. Pharmacol.20221383275010.3389/fphar.2022.83275035273506
     [Google Scholar]
  95. LiuS. YaoS. YangH. LiuS. WangY. Autophagy: Regulator of cell death.Cell Death Dis.2023141064810.1038/s41419‑023‑06154‑837794028
     [Google Scholar]
  96. RahimifardM. BaeeriM. MousaviT. AzarnezhadA. Haghi-AminjanH. AbdollahiM. Combination therapy of cisplatin and resveratrol to induce cellular aging in gastric cancer cells: Focusing on oxidative stress, and cell cycle arrest.Front. Pharmacol.202313106886310.3389/fphar.2022.106886336686661
     [Google Scholar]
  97. SamadiM. BaeeriM. Haghi-AminjanH. RahimifardM. GholamiM. HassaniS. SattariM. AzarmiY. BameriB. ArmandehM. Hooshangi ShayestehM.R. EghbalM.A. AbdollahiM. On the mechanisms of taurine in alleviating electrocardiographic, hemodynamic, and biochemical parameters following aluminum phosphide cardiotoxicity.Food Chem. Toxicol.202111234710.1016/j.fct.2021.112347
     [Google Scholar]
  98. Haghi-AminjanH. BaeeriM. RahimifardM. AlizadehA. HodjatM. HassaniS. AsghariM.H. AbdollahiA. DidariT. HosseiniR. SharifzadehM. AbdollahiM. The role of minocycline in alleviating aluminum phosphide-induced cardiac hemodynamic and renal toxicity.Environ. Toxicol. Pharmacol.201864264010.1016/j.etap.2018.09.00830290328
     [Google Scholar]
  99. LinR.W. HoC.J. ChenH.W. PaoY.H. ChenL.E. YangM.C. HuangS.B. WangS. ChenC.H. WangC. P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage.Cell Cycle201817172175218610.1080/15384101.2018.152056530198376
     [Google Scholar]
  100. PfefferC. SinghA. Apoptosis: A target for anticancer therapy.Int. J. Mol. Sci.201819244810.3390/ijms1902044829393886
     [Google Scholar]
  101. GuptaN. VermaK. NallaS. KulshreshthaA. LallR. PrasadS. Free radicals as a double-edged sword: The cancer preventive and therapeutic roles of curcumin.Molecules20202522539010.3390/molecules2522539033217990
     [Google Scholar]
  102. ZhaoY. YeX. XiongZ. IhsanA. AresI. MartínezM. Lopez-TorresB. Martínez-LarrañagaM.R. AnadónA. WangX. MartínezM.A. Cancer Metabolism: The role of ROS in DNA damage and induction of apoptosis in cancer cells.Metabolites202313779610.3390/metabo1307079637512503
     [Google Scholar]
  103. DongL-F. LowP. DyasonJ.C. WangX-F. ProchazkaL. WittingP.K. FreemanR. SwettenhamE. ValisK. LiuJ. ZobalovaR. TuranekJ. SpitzD.R. DomannF.E. SchefflerI.E. RalphS.J. NeuzilJ. α-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II.Oncogene200827314324433510.1038/onc.2008.6918372923
     [Google Scholar]
  104. SaeidniaS. AbdollahiM. Antioxidants: Friends or foe in prevention or treatment of cancer: The debate of the century.Toxicol. Appl. Pharmacol.20132711496310.1016/j.taap.2013.05.00423680455
     [Google Scholar]
  105. OnoueT. KangY. LefebvreB. SmithA.M. DenduluriS. CarverJ. FradleyM.G. ChittamsJ. Scherrer-CrosbieM. The association of metformin with heart failure in patients with diabetes mellitus receiving anthracycline chemotherapy.Cardiooncology20235567468210.1016/j.jaccao.2023.05.01337969650
     [Google Scholar]
  106. OsataphanN. PhrommintikulA. LeemasawatK. SomwangprasertA. ApaijaiN. SuksaiS. SirikulW. GunaparnS. ChattipakornS.C. ChattipakornN. Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: A randomized controlled trial.Sci. Rep.20231311275910.1038/s41598‑023‑40061‑437550350
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673320425240806051215
Loading
Unveiling the Protective Role of Metformin against Chemotherapy-induced Cardiotoxicity: A Comprehensive Scoping Review on Non-clinical Studies
Curr. Med. Chem. 32, 3069 (2025); https://doi.org/10.2174/0109298673320425240806051215
/content/journals/cmc/10.2174/0109298673320425240806051215
/content/journals/cmc/10.2174/0109298673320425240806051215
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): Cardiotoxicity; cisplatin; cyclophosphamide; doxorubicin; metformin; sunitinib

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test